News for ResApp Health Limited (RAP.AX)

Australian MedTech company Ceretas has successfully secured $1 million in seed funding to advance its low-cost, portable and non-invasive ultrasound

Pharmaceutical companies can bring new hope to patients by delivering solutions to unmet medical needs. They can go from small market cap plays to market giants – but getting there isn't easy, it’s risky, and it can take a lot of money and patience. Hosted by HotCopper and The Market Online's executive producer Sonia Madigan, this webinar demystifies the clinical trials & approvals process.

BlinkLab (ASX:BB1) has traded up as much as 50 per cent on listing on the ASX this morning, breaking the ASX IPO drought.

The ASX200 is up just over half a per cent – beating futures predictions - with all sectors glowing green mid-session.

The ASX200 is tipped to open 0.4 per cent higher. The performance of gold was a highlight overnight hitting US$2300 on ounce – equivalent to above A$3500 an ounce.

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is being led by chair Brian Leedman - a founder of ResApp Health - the cough analysis app sold to Pfizer two years ago in a $179 million deal.

Biotech tends to follow a four to five year market cycle and…

The global virtual diagnostics market is predicted to be valued at USD 1,512.2 million by 2027, registering a CAGR of 15.0%, according to the latest analysis by Emergen Research. The market is…

Burlingame, Jan. 23, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global life sciences analytics market is estimated to be valued...

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

Recent studies had shown the app had a 92 per cent success rate in diagnosing the virus among symptomatic patients, but more clinical trials were needed for it to gain regulatory approval.

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.

August was a solid month for stocks - and medicinal cannabis - despite 10 out of 11 sectors ending in the red.

Rebounding global equity markets managed to keep the spring in its step this week, despite the bad blood between analysts and August.

ASX Small Caps Lunch Wrap: Who else has learnt that it’s lonely at the top? bassa

ASX 200 is down, small caps surge late. Tech and consumer stocks lift while energy drags. Chinese markets higher on Pelosi goes to Taipei day.

The ASX has dropped again today, ResApp's Pfizer deal is back again and there's a horde of monkeys terrorising a Japanese city.

In a ground-breaking development, the US FDA has just approved a clinical trial studying the effects of naturally derived psychedelic drugs.

Closing Bell: Small caps jump 1.5% as exciting ideas about energy loom large across the ASX